Multiple myeloma: the (r)evolution of current therapy and a glance into future.
Haematologica
; 105(10): 2358-2367, 2020 10 01.
Article
en En
| MEDLINE
| ID: mdl-33054076
ABSTRACT
Over the past 20 years, the regulatory approval of several novel agents to treat multiple myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased understanding of MM biology has translated to advances in diagnosis, prognosis, and response assessment, as well as informed the development of targeted and immune agents. Here we provide an overview of the recent progress in MM, and highlight research areas of greatest promise to further improve patient outcome in the future.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Mieloma Múltiple
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Haematologica
Año:
2020
Tipo del documento:
Article
País de afiliación:
Estados Unidos